Google
×
Investor FAQs · Email Alerts · Contact Us · Investor Relations. News Release Details. Facebook · Twitter · Email; Tumblr; LinkedIn · News & Events · Stock ...
AveXis Reports First Quarter 2018 Financial and Operating Results · Cash Position: As of March 31, 2017, AveXis had $586.8 million in cash and cash equivalents.
We are conducting a pivotal clinical trial for AVXS‑101 for the treatment of SMA Type 1, the leading genetic cause of infant mortality. SMA Type 1 is a lethal ...
We are offering 3,960,145 shares of our common stock. PBM Capital Investments, LLC, the selling stockholder identified in this prospectus, is offering an ...
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports ( ...
Analysts and investors can participate in the conference call by dialing (844) 889-6863 for domestic callers and (661) 378-9762 for international callers, using ...
Missing: relations | Show results with:relations
People also ask
Apr 9, 2018 · Investor Relations. Page 2. Disclaimer. 2. This presentation ... 3 Agreement to Acquire AveXis | April 9, 2018 | Novartis Investor Presentation.
Retired Vice President, Investor Relations and Corporate Communications, AveXis, Inc. · View mutual connections with Jim · Welcome back · Activity · Experience.
May 5, 2019 · fSpeer259@avexis.com. Novartis Investor Relations. Central investor relations line: +41 61 324 7944. E-mail: investor.relations@novartis.com.
Jan 8, 2018 · “An expanded relationship further aligns REGENXBIO with AveXis in their commitment to develop and commercialize novel gene therapy treatments ...